血液病患者对SARS-COV-2 mRNA疫苗接种的免疫应答改变,表现为体液与T细胞免疫区室间交互作用受损
该研究分析血液病患者接种第二剂SARS-CoV-2 mRNA疫苗后21-28天的T细胞免疫应答及体液免疫。结果显示患者可产生T细胞应答,但CD4+与CD8+ T细胞协同激活模式较健康对照高度改变,且体液免疫应答与T细胞效应功能及免疫细胞组成不相关。
要点
- 血液病患者接种mRNA疫苗后可产生T细胞应答,但CD4+与CD8+ T细胞协同激活模式较健康对照高度改变。
- 血液病患者的体液免疫应答与T细胞效应功能及免疫细胞组成不相关。
- 数据表明血液病患者接种mRNA疫苗后T细胞免疫紊乱,体液与T细胞免疫区室间交互作用丧失。
核心结论
- 血液病患者接种SARS-CoV-2 mRNA疫苗后存在T细胞免疫紊乱,以及体液与T细胞免疫区室间交互作用丧失。
研究设计与样本
- 在接种第二剂mRNA疫苗后21-28天,采用酶联免疫斑点法(ELISpot)和流式细胞术分析不同疾病类型血液病患者的T细胞免疫应答,用抗SARS-CoV-2刺突受体结合域抗体检测描述体液B细胞应答,并通过免疫表型分析量化T和B细胞亚群。
主要发现
- 血液病患者接种SARS-CoV-2 mRNA疫苗可引发T细胞应答,但健康对照中CD4+与CD8+ T细胞一致参与的协同激活过程在患者中高度改变。
- 血液病患者的体液免疫应答与T细胞效应功能及免疫细胞组成不相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with hematologic diseases frequently develop insufficient humoral immunity following mRNA vaccination against SARS-COV-2. Data on the T-cellular immune response to SARS-COV-2 mRNA vaccination and its impact on the humoral compartment in this patient population is limited. METHODS: Here, we performed a detailed analysis of T-cellular immune responses 21-28 days after the second dose of mRNA vaccination in hematologic patients suffering from different disease entities using ELISpot assay and flow cytometry. Anti-SARS-CoV-2 spike receptor-binding domain antibody assays were performed to describe humoral B-cell response. To complement our cellular analysis, we quantified T- and B-cell subsets by immunophenotyping. FINDINGS: We show that SARS-CoV-2 mRNA vaccination elicits T-cell responses in patients suffering from hematologic diseases, but the orchestrated process of T-cell activation with a uniform involvement of CD4+ and CD8+ T-cells as seen in healthy controls was highly altered. Moreover, we observed that humoral immune response in hematologic patients was uncorrelated with T-cell effector function and immune cell composition. INTERPRETATION: Our data show disturbed T-cellular immunity and a loss of cross-talk between humoral and T-cellular immune compartments following mRNA vaccination in hematologic patients.
引用
- Hatzl S, Posch F, Schulz E, et al. Altered immune responses to mRNA vaccination against SARS-COV-2 are characterized by an impaired cross-talk between humoral and T-cellular immune compartments in patients with hematologic diseases. Vaccine. 2025. PMID: 40882265. doi:10.1016/j.vaccine.2025.127666
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。